1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7pyridinyl-imidazo[1,2-alpha]pyrimidin-5(1h)-one derivatives

Abstract

The invention relates to an imidazo[1,2-a]pyrimidone derivative represented by formula (1) or a salt thereof, wherein: X represents a bond, an ethenylene group, and ethenylene group, a methylene group optionally substituted by one or two groups selected from a Calkyl group, a hydroxy group and a Calkoxy group; a carbonyl group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxide group or a nitrogen atom being optionally substituted by a Calkyl group; R1 represents a 2,3 or 4-pyridyl group optionally substituted by a Calkyl group, Calkoxy group or a halogen atom; R2 represents a Calkyl group, a Cperhalogenated alkyl group, a Chalogenated alkyl group, a benzyl group, a phenyl ring, a naphthyl ring, 5,6,7,8-tetrahydronaphthyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring, the benzyl group and the rings being optionally substituted by 1 to 4 substituents selected from a Calkyl group, a phenyl ring, a halogen atom, a Cperhalogenated alkyl group, a Chalogenated alkyl group, a hydroxyl group, a Calkoxy group, a nitro, a cyano, an amino, a Cmonoalkylamino group or a Cdialkylamino group; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β, such as Alzheimer disease.